BridgeBio Pharma, Inc. (MUN:2CL)
Germany
· Delayed Price · Currency is EUR 62.18
+7.98 (14.72%)
At close: Dec 1, 2025
BridgeBio Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 570.12 | 681.1 | 375.94 | 376.69 | 393.77 | Upgrade
|
| Short-Term Investments | 17.36 | - | 58.95 | 95.23 | 442.89 | Upgrade
|
| Cash & Short-Term Investments | 587.48 | 681.1 | 434.88 | 471.92 | 836.66 | Upgrade
|
| Cash Growth | -13.74% | 56.62% | -7.85% | -43.59% | 37.81% | Upgrade
|
| Accounts Receivable | 139.44 | 4.72 | 1.75 | 17.08 | 19.75 | Upgrade
|
| Receivables | 139.44 | 4.72 | 1.75 | 17.08 | 19.75 | Upgrade
|
| Inventory | 26.75 | - | - | - | - | Upgrade
|
| Prepaid Expenses | 38.42 | 31.04 | 24.31 | 21.92 | 32.27 | Upgrade
|
| Restricted Cash | 0.55 | 0.13 | 16.65 | 37.93 | 0.18 | Upgrade
|
| Other Current Assets | 5.1 | 3.7 | - | - | - | Upgrade
|
| Total Current Assets | 797.75 | 720.69 | 477.59 | 548.85 | 888.86 | Upgrade
|
| Property, Plant & Equipment | 13.52 | 12.78 | 19.84 | 25.25 | 45.97 | Upgrade
|
| Long-Term Investments | 79.97 | 143.75 | 1.6 | - | - | Upgrade
|
| Other Intangible Assets | 28.08 | 23.93 | 26.32 | 28.71 | 44.93 | Upgrade
|
| Other Long-Term Assets | 16.71 | 18.2 | 21.03 | 20.22 | 33.03 | Upgrade
|
| Total Assets | 936.03 | 919.34 | 546.38 | 623.04 | 1,013 | Upgrade
|
| Accounts Payable | 36.23 | 9.62 | 10.66 | 11.56 | 11.88 | Upgrade
|
| Accrued Expenses | 238.36 | 124.08 | 116.97 | 95.54 | 116.75 | Upgrade
|
| Current Portion of Leases | 6.19 | 4.51 | 4.13 | 3.68 | 4.94 | Upgrade
|
| Current Unearned Revenue | 7.19 | 14.6 | 6.1 | 8.16 | - | Upgrade
|
| Other Current Liabilities | - | 1.6 | 6 | 2.5 | 1.5 | Upgrade
|
| Total Current Liabilities | 287.97 | 154.4 | 143.84 | 121.43 | 135.07 | Upgrade
|
| Long-Term Debt | 1,852 | 1,721 | 1,727 | 1,708 | 1,704 | Upgrade
|
| Long-Term Leases | 3.81 | 4.7 | 8.98 | 12.27 | 17.43 | Upgrade
|
| Long-Term Unearned Revenue | 13.08 | 17.1 | 3.73 | 7.1 | - | Upgrade
|
| Other Long-Term Liabilities | 855.27 | 479.38 | 5.63 | 19.54 | 22.07 | Upgrade
|
| Total Liabilities | 3,013 | 2,377 | 1,889 | 1,868 | 1,878 | Upgrade
|
| Common Stock | 0.2 | 0.2 | 0.18 | 0.16 | 0.15 | Upgrade
|
| Additional Paid-In Capital | 2,058 | 1,903 | 1,481 | 938.7 | 841.53 | Upgrade
|
| Retained Earnings | -3,821 | -3,096 | -2,561 | -1,918 | -1,437 | Upgrade
|
| Treasury Stock | -323.28 | -275 | -275 | -275 | -275 | Upgrade
|
| Comprehensive Income & Other | 0.01 | 0.01 | 0.03 | -0.33 | -0.13 | Upgrade
|
| Total Common Equity | -2,087 | -1,468 | -1,354 | -1,255 | -870.41 | Upgrade
|
| Minority Interest | 10.03 | 10.29 | 11.72 | 9.69 | 4.84 | Upgrade
|
| Shareholders' Equity | -2,077 | -1,458 | -1,343 | -1,245 | -865.58 | Upgrade
|
| Total Liabilities & Equity | 936.03 | 919.34 | 546.38 | 623.04 | 1,013 | Upgrade
|
| Total Debt | 1,862 | 1,731 | 1,740 | 1,724 | 1,726 | Upgrade
|
| Net Cash (Debt) | -1,275 | -1,049 | -1,305 | -1,252 | -889.51 | Upgrade
|
| Net Cash Per Share | -6.66 | -5.64 | -8.02 | -8.49 | -6.16 | Upgrade
|
| Filing Date Shares Outstanding | 193.86 | 190.19 | 175.83 | 151.37 | 147.61 | Upgrade
|
| Total Common Shares Outstanding | 194.77 | 190.04 | 175.08 | 150.63 | 147.34 | Upgrade
|
| Working Capital | 509.78 | 566.29 | 333.75 | 427.43 | 753.79 | Upgrade
|
| Book Value Per Share | -10.71 | -7.72 | -7.73 | -8.33 | -5.91 | Upgrade
|
| Tangible Book Value | -2,115 | -1,492 | -1,381 | -1,283 | -915.35 | Upgrade
|
| Tangible Book Value Per Share | -10.86 | -7.85 | -7.89 | -8.52 | -6.21 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.